Visual cycle modulators versus placebo or observation for the prevention and treatment of geographic atrophy due to age-related macular degeneration.
CONCLUSIONS: There is limited evidence to support the use of visual cycle modulators (emixustat and fenretinide) for the treatment of established geographic atrophy due to AMD. The possible reduction in the incidence of CNV observed with fenretinide, and to a lesser extent, emixustat, requires formal assessment in focused studies.
PMID: 33331670 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Yeong JL, Loveman E, Colquitt JL, Royle P, Waugh N, Lois N Tags: Cochrane Database Syst Rev Source Type: research
More News: Age-Related Macular Degeneration (AMD) | Clinical Trials | Databases & Libraries | Diabetes | Disability | Endocrinology | Eyes | General Medicine | Germany Health | Opthalmology | Science | Study | Websites